泛昔洛韦治疗DNA聚合酶基因552位不同突变的慢性乙型肝炎患者的疗效。 - Suppr | 超能文献

Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene.

作者信息

Wolters L M, Honkoop P, Niesters H G, de Man R A

出版信息

J Hepatol. 1998 May;28(5):909-10. doi: 10.1016/s0168-8278(98)80243-2.

DOI:10.1016/s0168-8278(98)80243-2

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene.泛昔洛韦治疗DNA聚合酶基因552位不同突变的慢性乙型肝炎患者的疗效。

J Hepatol. 1998 May;28(5):909-10. doi: 10.1016/s0168-8278(98)80243-2.

2

Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a.泛昔洛韦或拉米夫定与α-2a干扰素序贯联合治疗HBe抗原阴性/病毒DNA阳性的慢性乙型肝炎

Liver Int. 2004 Apr;24(2):98-104. doi: 10.1111/j.1478-3231.2004.0889.x.

3

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation.肝移植后在乙肝免疫球蛋白（HBIg）免疫情况下发生乙肝病毒再感染患者中，使用泛昔洛韦和拉米夫定序贯治疗时乙肝病毒的突变模式

Hepatology. 1999 Jul;30(1):244-56. doi: 10.1002/hep.510300141.

4

Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain.在西班牙随机挑选的慢性乙肝携带者中检测对拉米夫定和泛昔洛韦耐药的乙肝病毒变异体。

Enferm Infecc Microbiol Clin. 2004 Mar;22(3):133-7. doi: 10.1016/s0213-005x(04)73051-7.

5

Famciclovir treatment of chronic hepatitis B in heart transplant recipients: a prospective trial.

Transplantation. 1999 Nov 27;68(10):1503-11. doi: 10.1097/00007890-199911270-00013.

6

Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: results of 24 weeks of therapy.拉米夫定与泛昔洛韦治疗亚洲慢性乙型肝炎患者的疗效比较：24周治疗结果

J Med Virol. 2002 Jul;67(3):334-8. doi: 10.1002/jmv.10075.

7

Cell-mediated immune responses and loss of hepatitis B e-antigen (HBeAg) during successful lamivudine and famciclovir combination therapy for chronic replicating hepatitis B virus infection.在拉米夫定和泛昔洛韦联合治疗慢性乙型肝炎病毒复制感染成功期间的细胞介导免疫反应和乙肝e抗原（HBeAg）丢失

Clin Infect Dis. 1999 Dec;29(6):1575-7. doi: 10.1086/313518.

8

Antiviral combination therapy for lamivudine-resistant hepatitis B reinfection after liver transplantation.肝移植后拉米夫定耐药乙型肝炎再感染的抗病毒联合治疗

Transpl Int. 2000;13 Suppl 1:S359-62. doi: 10.1007/s001470050361.

9

Disappearance of hepatitis B virus core deletion mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine.

Transpl Int. 1999;12(4):283-7. doi: 10.1007/s001470050225.

10

The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.一名再次感染乙型肝炎的肝移植受者中病毒突变的相继出现：乙型肝炎免疫球蛋白逃逸、泛昔洛韦无反应，随后出现拉米夫定耐药，导致移植物丧失。

J Hepatol. 1998 Oct;29(4):669-75. doi: 10.1016/s0168-8278(98)80164-5.

引用本文的文献

1

Failure of the lamivudine-resistant rtM204I hepatitis B virus mutants to efficiently support hepatitis delta virus secretion.拉米夫定耐药的rtM204I乙肝病毒突变体无法有效支持丁型肝炎病毒的分泌。

J Virol. 2005 May;79(10):6570-3. doi: 10.1128/JVI.79.10.6570-6573.2005.

2

Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.使用编码乙型肝炎病毒耐药株的新型重组杆状病毒进行抗乙肝病毒化合物的交叉耐药性检测。

Antimicrob Agents Chemother. 2001 Jun;45(6):1705-13. doi: 10.1128/AAC.45.6.1705-1713.2001.

3

Treatment of chronic hepatitis B: new antiviral therapies.慢性乙型肝炎的治疗：新的抗病毒疗法

Curr Gastroenterol Rep. 1999 Feb-Mar;1(1):20-6. doi: 10.1007/s11894-999-0082-7.